TREAMENT OF EARLY AGE MANIA (TEAM)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的总体目的是对患有DSM-IV（躁狂或混合期）或躁狂的6.0-15岁（N=540）进行一项协作性、多地点精神药理学有效性研究。该方案的具体目的是：(1)调查锂、丙戊酸盐和利培酮作为单一疗法和附加药物治疗儿童BP-1（躁狂或混合期）障碍的有效性；(2)试点一个复杂的、多层次的、适应性策略设计；(3)探索社会心理因素对停药、依从性和结局的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall aim of this study is to perform a collaborative, multisite psychopharmacology effectiveness study of 6.0-15 years old (N=540) who have DSM-IV (mania or mixed phase) or mania. The specific aims of this protocol are: (1) To investigate the effectivness of lithium, valproate and resperidone as monotherapy and as add-on agents for childhood BP-1 (manic or mixed phase) disorder (2) To pilot a complex, multistrata, adaptive strategy design (3) to explore the effects of psychosocial factors on discontinuation, compliance and outcome.